Helex - About the company
Helex is a seed company based in New York City (United States), founded in 2021 by Rohini Kalvakuntla, Poulami Chaudhuri and Anirudh Nishtala. It operates as a Provider of next-generation gene-editing therapies. Helex has raised $6M in funding from IndieBio and pi Ventures. The company has 926 active competitors, including 310 funded and 184 that have exited. Its top competitors include companies like Alnylam, Forge Biologics and Strand Therapeutics.
Company Details
Provider of next-generation gene-editing therapies. By using proprietary genomics data, bioinformatics, and intelligent data-driven platform the company has developed CRISPR-based genome editing therapeutics.
- Website
- www.helex.bio/
- Email ID
- *****@helex.bio
Key Metrics
Founded Year
2021
Location
New York City, United States
Stage
Seed
Total Funding
$6M in 2 rounds
Latest Funding Round
Ranked
43rd among 926 active competitors
Employee Count
37 as on Sep 30, 2026
Legal entities associated with Helex
Helex is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
HELEX INC. CIN: 7008149 , United States, Active | Jun 13, 2023 | - | - | - |
Sign up to download Helex's company profile
Helex's funding and investors
Helex has raised a total funding of $6M over 2 rounds. Its first funding round was on Oct 02, 2021. Its latest funding round was a Seed round on Oct 24, 2025 for $*****. 3 investors participated in its latest round. Helex has 4 institutional investors.
Here is the list of recent funding rounds of Helex:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 24, 2025 | 5047710 | Seed | 1630587 | 1671521 | 5309802 | 6254837 |
Oct 02, 2021 | 1413935 | Seed | 3365392 | 1353753 | 1036269 |
Access funding benchmarks and valuations. Sign up today!View details of Helex's funding rounds and investors
Helex's founders and board of directors
Founder? Claim ProfileThe founders of Helex are Rohini Kalvakuntla, Poulami Chaudhuri and Anirudh Nishtala. Poulami Chaudhuri is the CEO of Helex.
Here are the details of Helex's key team members:
- Rohini Kalvakuntla: Co-Founder & CBO of Helex and founder of 2 other companies, RED and Empower Labs. They serve on the boards of 2 companies.Contact Info: 1 email address and 1 phone number
- Poulami Chaudhuri: Co-Founder & CEO of Helex. Contact Info: 1 email address
- Anirudh Nishtala: Co-Founder & COO of Helex.
View details of Helex's Founder profiles and Board Members
Helex's employee count trend
Helex has 37 employees as of Sep 26. Here is Helex's employee count trend over the years:
Uncover Helex's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Helex's Competitors and alternates
Top competitors of Helex include Alnylam, Forge Biologics and Strand Therapeutics. Here is the list of Top 10 competitors of Helex, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 81/100 | |
2nd |  Forge Biologics 2020, Columbus (United States), Acquired | Developer of gene therapeutic solutions for treating multiple diseases | $330M | 72/100 | |
3rd |  Strand Therapeutics 2017, Cambridge (United States), Series B | Provider of platform to deliver mRNA therapeutics for multi functional treatments | $256M | 71/100 | |
4th | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 69/100 | |
5th | Liquidia 2004, Morrisville (United States), Public | Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions | $90.3M | 69/100 | |
6th | Ionis 1989, United States, Public | Developer of RNA-targeted medicines for various diseases | - | 69/100 | |
7th | Stoke Therapeutics 2014, Bedford (United States), Public | Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing | $131M | 68/100 | |
8th | Intellia Therapeutics 2014, Cambridge (United States), Public | Developer of genome editing therapeutics using CRISPR and Cas9 technology | $85M | 68/100 | |
9th |  Dyne Therapeutics 2017, Cambridge (United States), Public | Developer of nucleic acid therapies for rare diseases | $166M | 67/100 | |
10th | Aspen Neuroscience 2018, San Diego (United States), Series C | Provider of genomic-based personalised pluripotent stem cell therapy | $339M | 67/100 | |
43rd |  Helex 2021, New York City (United States), Seed | Provider of next-generation gene-editing therapies | $6M | 61/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Helex's competitors? Click here to see the top ones
Helex's Investments and acquisitions
Helex has made no investments or acquisitions yet.
Reports related to Helex
Here is the latest report on Helex's sector:
News related to Helex
Media has covered Helex for a total of 4 events in the last 1 year, 1 of them has been about company updates.
•
•
India’s healthcare funding reaches $97.6M in October 2025Express Healthcare•Nov 03, 2025•The Eye Foundation, Helex, August AI, Neulife and 2 others
•
Biotech startup Helex raises $3.5M to advance gene therapies for kidney diseasesYourStory•Oct 30, 2025•Helex, Bluehill Capital, SOSV, pi Ventures and 2 others
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Helex
Explore our recently published companies
